Skip to main content
Equibles

NATIXIS ADVISORS, LLC

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 1018331 Boston, MA
Back to ACAD Full portfolio

Position in ACAD

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$3,439,737
+$1,204,856 QoQ
Shares Held
135,958
+35.4% QoQ
Ownership
0.079%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#91
of 354 holders
Holding Since
Mar 2023
14 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

NATIXIS ADVISORS, LLC holds $495,549,179 across 38 Biotechnology names. ACAD ranks #18 (0.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 448,631 $222,848,476
2 REGN
Regeneron Pharmaceuticals, Inc.
 129,236 $80,583,815
3 TECH
BIO-TECHNE Corp
 818,905 $57,855,638
4 ALNY
Alnylam Pharmaceuticals, Inc.
 75,311 $22,670,870
5 ARGX
Argenx SE
 19,088 $17,709,273
6 INSM
INSMED Inc
 73,607 $7,847,978
7 HALO
Halozyme Therapeutics, Inc.
 97,536 $7,634,142
8 JAZZ
Jazz Pharmaceuticals plc
 29,928 $7,211,749

All Filings in ACAD

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $3,439,737 135,958
2026-03-31 $2,234,881 100,399
2025-12-31 $1,913,824 71,652
2025-09-30 $1,370,753 64,234
2025-06-30 $1,556,879 72,178
2025-03-31 $1,044,685 62,895
2024-12-31 $862,578 47,007
2024-09-30 $622,705 40,488
2024-06-30 $414,813 25,527
2024-03-31 $329,676 17,830
2023-12-31 $1,279,796 40,875
2023-09-30 $724,460 34,763
2023-06-30 $600,833 25,087
2023-03-31 $263,047 13,977